Xilio Therapeutics, Inc. 8-K

What Happened

• On January 8, 2026, Xilio Therapeutics, Inc. announced corporate updates in a press release (furnished as Exhibit 99.1) including an estimate of cash and cash equivalents of approximately $137.5 million as of December 31, 2025.
• The company also disclosed a board leadership change: Sara M. Bonstein was appointed chair of the Board on January 8, 2026. She succeeds Paul Clancy, who retired from the Board effective January 6, 2026; the filing states his retirement was not due to any disagreement with the company or management.

Key Details

• Report date / filing: January 8, 2026 (Current Report on Form 8-K).
• Cash and cash equivalents: approximately $137.5 million as of December 31, 2025 (Item 2.02 — Results of Operations and Financial Condition).
• Board change: Sara M. Bonstein named Board chair effective January 8, 2026; Paul Clancy retired effective January 6, 2026 (Item 5.02).
• Press release: furnished as Exhibit 99.1 to the 8-K.

Why It Matters

• The reported cash balance gives investors a snapshot of Xilio’s near-term liquidity and financial position heading into upcoming milestones (provides context even though this is not a full quarterly earnings report).
• A change in board chair is a governance event investors track; the filing notes the prior chair’s retirement was not due to disagreement, and no management departures were reported.
• These disclosures are factual updates on Xilio’s financial resources and board leadership that may influence investor assessment of the company’s readiness to advance planned programs.